Trials / Approved For Marketing
Approved For MarketingNCT03780140
Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Shionogi · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
Expanded access may be provided for cefiderocol for qualified patients who have limited treatment options and are not eligible for a clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cefiderocol | Cefiderocol for intravenous infusion |
Timeline
- First posted
- 2018-12-19
- Last updated
- 2020-02-28
Source: ClinicalTrials.gov record NCT03780140. Inclusion in this directory is not an endorsement.